Oncolytic viruses and immunity

被引：75

作者：

Chaurasiya, Shyambabu ^{[1
]}

Chen, Nanhai G. ^{[1
,2
,3
]}

Fong, Yuman ^{[1
,2
]}

机构：

[1] City Hope Natl Med Ctr, Dept Surg, 1500 E Duarte Rd, Duarte, CA 91010 USA

[2] City Hope Natl Med Ctr, Beckman Res Inst, Ctr Gene Therapy, Dept Hematol & Hematopoiet Cell Transplantat, Duarte, CA 91010 USA

[3] City Hope Natl Med Ctr, Beckman Res Inst, Gene Editing & Viral Vector Core, Duarte, CA 91010 USA

来源：

CURRENT OPINION IN IMMUNOLOGY | 2018年 / 51卷

基金：

美国国家卫生研究院;

关键词：

NEWCASTLE-DISEASE VIRUS; HERPES-SIMPLEX-VIRUS; DENDRITIC CELLS; T-CELLS; PATHOGEN RECOGNITION; ANTITUMOR-ACTIVITY; PHASE-I; CANCER; REOVIRUS; THERAPY;

D O I：

10.1016/j.coi.2018.03.008

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Initially, direct oncolysis was thought to be the sole mechanism through which oncolytic viruses (OVs) exert their anti-tumor effect, and the immune system was perceived as the major obstacle in oncolytic virotherapy. Over the last decade, there has been a lot of debate on whether the immune system is a friend or foe of OVs. However, we are now at a stage where the initial thinking has been reversed as a result of compelling evidence that the immune system plays a critical role in the success of oncolytic virotherapy. In this review we discuss the importance of the involvement of innate and adaptive immunity for therapeutic efficacy of OVs, and the rational combination of OVs with other immunotherapies for further enhancement of overall therapeutic outcome.

引用

页码：83 / 90

页数：8

共 72 条

[1] Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma [J].

Andtbacka, Robert H. I. ;

Kaufman, Howard L. ;

Collichio, Frances ;

Amatruda, Thomas ;

Senzer, Neil ;

Chesney, Jason ;

Delman, Keith A. ;

Spitler, Lynn E. ;

Puzanov, Igor ;

Agarwala, Sanjiv S. ;

Milhem, Mohammed ;

Cranmer, Lee ;

Curti, Brendan ;

Lewis, Karl ;

Ross, Merrick ;

Guthrie, Troy ;

Linette, Gerald P. ;

Daniels, Gregory A. ;

Harrington, Kevin ;

Middleton, Mark R. ;

Miller, Wilson H., Jr. ;

Zager, Jonathan S. ;

Ye, Yining ;

Yao, Bin ;

Li, Ai ;

Doleman, Susan ;

VanderWalde, Ari ;

Gansert, Jennifer ;

Coffin, Robert S. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (25) :2780-U98

[2]

Apostolidis L, 2007, INT J ONCOL, V31, P1009

[3] Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy [J].

Bai, Fuliang ;

Niu, Zeshan ;

Tian, Hui ;

Li, Siming ;

Lv, Zheng ;

Zhang, Tianyuan ;

Ren, Guiping ;

Li, Deshan .

IMMUNOLOGY LETTERS, 2014, 159 (1-2) :36-46

[4] Emerging role of Natural killer cells in oncolytic virotherapy [J].

Bhat, Rauf ;

Rommelaere, Jean .

IMMUNOTARGETS AND THERAPY, 2015, 4 :65-77

[5] Enhancement of NK cell antitumor responses using an oncolytic parvovirus [J].

Bhat, Rauf ;

Dempe, Sebastian ;

Dinsart, Christiane ;

Rommelaere, Jean .

INTERNATIONAL JOURNAL OF CANCER, 2011, 128 (04) :908-919

[6] Recombinant Vesicular Stomatitis Virus Transduction of Dendritic Cells Enhances Their Ability to Prime Innate and Adaptive Antitumor Immunity [J].

Boudreau, Jeanette E. ;

Bridle, Byram W. ;

Stephenson, Kyle B. ;

Jenkins, Kristina M. ;

Brunelliere, Jerome ;

Bramson, Jonathan L. ;

Lichty, Brian D. ;

Wan, Yonghong .

MOLECULAR THERAPY, 2009, 17 (08) :1465-1472

[7] Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8+ T-cell responses to anticancer vaccines [J].

Bridle, Byram W. ;

Clouthier, Derek ;

Zhang, Liang ;

Pol, Jonathan ;

Chen, Lan ;

Lichty, Brian D. ;

Bramson, Jonathan L. ;

Wan, Yonghong .

ONCOIMMUNOLOGY, 2013, 2 (08)

[8] To Infection and Beyond: The Multi-Pronged Anti-Cancer Mechanisms of Oncolytic Viruses [J].

Cassady, Kevin A. ;

Haworth, Kellie B. ;

Jackson, Josh ;

Markert, James M. ;

Cripe, Timothy P. .

VIRUSES-BASEL, 2016, 8 (02)

[9] Reovirus therapy of tumors with activated Ras pathway [J].

Coffey, MC ;

Strong, JE ;

Forsyth, PA ;

Lee, PWK .

SCIENCE, 1998, 282 (5392) :1332-1334

[10] Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent dendritic cells [J].

Dai, Peihong ;

Wang, Weiyi ;

Yang, Ning ;

Serna-Tamayo, Cristian ;

Ricca, Jacob M. ;

Zamarin, Dmitriy ;

Shuman, Stewart ;

Merghoub, Taha ;

Wolchok, Jedd D. ;

Deng, Liang .

SCIENCE IMMUNOLOGY, 2017, 2 (11)

← 1 2 3 4 5 6 7 8 →